Search results
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 3 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
Clinical Trials Arena via Yahoo Finance· 7 days agoIn May this year, the company reported that Tremfya (guselkumab) was superior to its Stelara...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 3 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks· 3 days agoJune 21, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the ...
Drug Names: The machinations behind the monikers
Quartz· 6 days agoIn fact, naming a prescription drug can take a manufacturer up to four years, as a set of three monikers per medicine must run the gauntlet of several regulatory agencies. It all starts with ...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 3 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks· 3 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
Zacks· 4 days agoOf these, at present, Eli Lilly appears to be a great stock to have in one’s portfolio based on its strong overall financial performance and robust drug pipeline. Lilly, with a market cap of ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the nod from the FDA, Skyrizi joins Rinvoq as immunology drugs in the AbbVie pipeline approved for both IBD conditions, UC and Crohn's. With the arrival of biosimilar competition for its ...